[Leukocytapheresis for ulcerative colitis].
Major inclusion criteria for leukocytapheresis (LCAP) therapy were mainly insufficient response to conventional drugs therapy. LCAP was administered once a week for 5 weeks of intensive therapy and once approximately a month for maintenance therapy, for 38 patients with UC. LCAP could remove approximately 1 x 10(10) white blood cells in each session. In the evaluation, we classified the response to the LCAP as: 1) excellent, 2) moderately improved, 3) no change, and 4) deterioration. Clinical improvement was recognized in 29 of 38 patients (76%) including 8 with dramatic response during the intensive therapy, and continued throughout the maintenance therapy in 26 patients (68.4%). Even though their symptoms were mild, the patients with more than 5 years UC history seemed to be not effective. The patients with moderately improvement and with excellent response have kept remission for about 20 months and about 2.5 years on an average, respectively. Clinical and blood examinations showed no side effects in any cases. It suggests that LCAP is able to be a UC treatment between drug therapies and an operation.
Sawada
K
K
Department of Internal Medicine 4, Hyogo College of Medicine, Nishinomiya, Japan.
Ohnishi
K
K
Kosaka
T
T
Egashira
A
A
Yamamura
M
M
Satomi
M
M
Shimoyama
T
T
D000328:Adult; D003093:Colitis, Ulcerative / Q000628:therapy*; D016099:Endoscopy, Gastrointestinal; D005260:Female; D006801:Humans; D007937:Leukapheresis; D010289:Parenteral Nutrition, Total; D011239:Prednisolone / Q000008:administration & dosage
D011239:Prednisolone